LEXX Stock Analysis: Buy, Sell, or Hold?
LEXX - Lexaria Bioscience Corp. Common Stock
$1.04
0.17 (20.08%)
▲
5d:
+38.59%
30d:
+46.69%
90d:
+68.56%
WAIT
LOW Confidence
Analysis Updated: Apr 2, 2026 12:00 AM ET
Earnings: Apr 13, 2026
10d
Get Alerted When LEXX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR BETTER ENTRY: LEXX is 26.8% above fair value ($0.82). While momentum could continue, risk/reward favors waiting for a pullback.
⏸️ WAIT FOR BETTER ENTRY: LEXX is 26.8% above fair value ($0.82). While momentum could continue, risk/reward favors waiting for a pullback.
In-depth Analysis How we analyze
Valuation Analysis: LEXX is currently trading at $1.04, which is considered extended relative to its 30-day fair value range of $0.67 to $0.82.
Technical Outlook: Technically, LEXX is in a downtrend. The price is approaching resistance at $1.02. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 20.1% recently.
Market Sentiment: LEXX has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $3.75 (+260.6%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, LEXX is in a downtrend. The price is approaching resistance at $1.02. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 20.1% recently.
Market Sentiment: LEXX has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $3.75 (+260.6%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Fair Price Range
$0.67 -
$0.82
Company Quality Score
57/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
57.9%
All Signals
- BEARISH: Price significantly overextended (+26.8% above fair value)
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+20.1%)
- BULLISH: Trading 260.6% below Wall St target ($3.75)
- WARNING: Recommendation downgraded due to 26.8% overvaluation
Fair Price Analysis
30-Day Fair Range
$0.67 -
$0.82
Current vs Fair Value
EXTENDED
Support & Resistance Levels
Support Level
$0.70
Resistance Level
$1.02
Current Trend
Downtrend
Technical data as of
Apr 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-3.35
Wall Street Target
$3.75
(+260.6%)
Revenue Growth (YoY)
107.1%
Share & Embed Analysis
Last updated: April 02, 2026 5:48 PM ET
Data refreshes hourly during market hours. Next update: 6:48 PM
Data refreshes hourly during market hours. Next update: 6:48 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is LEXX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$89 | 65 BUY |
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$58 | 57 HOLD |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$84 | 61 BUY |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1018 | 56 HOLD |
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$547 | 50 HOLD |
